Welcome to Valicare!

GMP consulting and compliance is one of our strengths. Whether GAP analyses, conceptual design, updating or implementation of a GMP system our GMP experts support you competently and efficiently.
Learn more
Visit our exhibition booth no.3 at the German Biotechnology Days in Stuttgart from 20-21.09.2021
Learn more

Services

News

27th of May 2021: Novelties by EMA on medicinal products with genetically modified cells

Updated EMA guideline for medicinal products containing modified cells provides innovations, recommendations and improvements to be implemented.
15th of April 2021: Toxicological assessment continues to gain acceptance for cleaning validation

WHO publishes decision on setting acceptance criteria for cleaning validation.
10th of February 2021: FDA approves Breyanzi®, a new CAR-T cell therapy drug

Fourth approved CAR-T cell therapy soon to be available in Europe?
4th of February 2021: Vaccinations with mRNA-based medicinal products

How do mRNA-based medicinal products work and how safe are they?
8th of January 2021: Integrated Qualification and Validation Guide

New ECA guide helps saving time and money by customer-supplier partnership on qualification and validation.
2th of December 2020: Good Manufacturing Practice (GMP)

The "Good Manufacturing Practice" and the "GMP Certificate" are mandatory for pharmaceutical manufacturers. They ensure the quality of medicinal products and active substances and protect the consumer.

Events

07 Jun 2022

08 Jun 2022

Frankfurt am Main/Germany 2nd APV Interactive Workshop on ATMP, 07.06. – 08.06.2022, Frankfurt am Main/ Deutschland The workshop focuses on Advanced Therapy Medical Products (ATMP) as products in development for market supply.

Show all events

Nachrichten aus aller Welt

Unser internationaler Pressespiegel zeigt eine Auswahl an Nachrichten und neusten Artikel zu den Themen Arzneimittel neuartiger Therapien (ATMP), Chimäre Antigenrezeptor(CAR)-T-Zell-Therapie, Tumor infiltrierende Lymphozyten (TIL) und biotechnologisch bearbeitete Gewebeprodukte (TEP).

The use of adipose tissue and its derivates to stimulate and support wound healing processes - An updated review

10.09.2021 | Science Direct

Highlights • The cost of isolation, purification, and population of adipose derived stem cells limits their widespread use. • The benefit ...

Gewebekultur im All

10.09.2021 | Medizin & Technik

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

10.09.2021 | Frontiers

Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in ...

Elevating Patient Care with Additive Manufacturing

10.09.2021 | Manufacturing Engineering

The field of health care is often considered to be one of the most dynamic. The speed at which innovation is occurring—from the way ...

Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®

09.09.2021 | World Pharma News

Where AI and Immunotherapy Converge to Reprogram Immunity

09.09.2021 | Bio Space

Published: Sep 09, 2021 By Heather McKenzie Immunai Co-founder and CTO Luis Voloch/Courtesy of Immunai. The roles of artificial ...

Targeted Therapies, Immunotherapies Lead the Way to Optimal Benefit in T-ALL

08.09.2021 | Targeted Oncology

Over the past 60 years, overall improvements in the cure rate for patients with T-cell acute lymphoblastic leukemia (T-ALL) have been one ...

CDMO Trends: End-to-End Service Providers

08.09.2021 | DCAT Value Chain Insights

Will the trend of combining API and drug-product development and manufacturing services into a “one-stop shop” business model for CDMOs ...

FDA Summit on Gene Therapy Risks Proves Timely

07.09.2021 | Bio Space

Published: Sep 07, 2021 By Heather McKenzie When the U.S . Food and Drug Administration (FDA) met last week to discuss gene therapy ...

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma

07.09.2021 | Frontiers

Immune escape is an early phenomenon in cancer development/progression. Indoleamine 2,3-dioxygenase 1 (IDO1) is a normal endogenous ...

Valicare – competent, reliable & efficient

You have little time and still want to know what services Valicare GmbH offers?

Download: service portfolio.

Business Areas

Any questions?

Stay up-to-date!

News and Information

Services

News

27th of May 2021: Novelties by EMA on medicinal products with genetically modified cells

15th of April 2021: Toxicological assessment continues to gain acceptance for cleaning validation

10th of February 2021: FDA approves Breyanzi®, a new CAR-T cell therapy drug

4th of February 2021: Vaccinations with mRNA-based medicinal products

8th of January 2021: Integrated Qualification and Validation Guide

2th of December 2020: Good Manufacturing Practice (GMP)

Events

Nachrichten aus aller Welt

The use of adipose tissue and its derivates to stimulate and support wound healing processes - An updated review

Gewebekultur im All

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

Elevating Patient Care with Additive Manufacturing

Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®

Where AI and Immunotherapy Converge to Reprogram Immunity

Targeted Therapies, Immunotherapies Lead the Way to Optimal Benefit in T-ALL

CDMO Trends: End-to-End Service Providers

FDA Summit on Gene Therapy Risks Proves Timely

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma

Blutgefäß wächst in künstlicher Umgebung

Clinical Catch-Up: August 30-September 3

CAR T-Cell Therapy P-PSMA-101 Demonstrates Promising Early Data in mCRPC

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation

Valicare – competent, reliable & efficient

Business Areas

Any questions?

Stay up-to-date!

Welcome to Valicare!

Services

News

27th of May 2021: Novelties by EMA on medicinal products with genetically modified cells

15th of April 2021: Toxicological assessment continues to gain acceptance for cleaning validation

10th of February 2021: FDA approves Breyanzi®, a new CAR-T cell therapy drug

4th of February 2021: Vaccinations with mRNA-based medicinal products

8th of January 2021: Integrated Qualification and Validation Guide

2th of December 2020: Good Manufacturing Practice (GMP)

Events

Nachrichten aus aller Welt

The use of adipose tissue and its derivates to stimulate and support wound healing processes - An updated review

Gewebekultur im All

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

Elevating Patient Care with Additive Manufacturing

Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®

Where AI and Immunotherapy Converge to Reprogram Immunity

Targeted Therapies, Immunotherapies Lead the Way to Optimal Benefit in T-ALL

CDMO Trends: End-to-End Service Providers

FDA Summit on Gene Therapy Risks Proves Timely

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma

Blutgefäß wächst in künstlicher Umgebung

Clinical Catch-Up: August 30-September 3

CAR T-Cell Therapy P-PSMA-101 Demonstrates Promising Early Data in mCRPC

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation

Valicare – competent, reliable & efficient

Business Areas

Any questions?

Stay up-to-date!

Define your privacy settings